Cue Biopharma (FRA:1UC) FCF Margin % : -225.58% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cue Biopharma's Free Cash Flow for the three months ended in Sep. 2024 was €-6.78 Mil. Cue Biopharma's Revenue for the three months ended in Sep. 2024 was €3.01 Mil. Therefore, Cue Biopharma's FCF Margin % for the quarter that ended in Sep. 2024 was -225.58%.

As of today, Cue Biopharma's current FCF Yield % is -57.75%.

The historical rank and industry rank for Cue Biopharma's FCF Margin % or its related term are showing as below:

FRA:1UC' s FCF Margin % Range Over the Past 10 Years
Min: -3371.65 Med: -970.52 Max: -266.05
Current: -403.11

During the past 9 years, the highest FCF Margin % of Cue Biopharma was -266.05%. The lowest was -3371.65%. And the median was -970.52%.

FRA:1UC's FCF Margin % is ranked worse than
63.73% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs FRA:1UC: -403.11

Cue Biopharma FCF Margin % Historical Data

The historical data trend for Cue Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma FCF Margin % Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-891.97

-1,048.94

-266.04

-3,372.43

-727.93

Cue Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-371.34	-601.68	-572.91	-376.27	-225.58

Competitive Comparison of Cue Biopharma's FCF Margin %

For the Biotechnology subindustry, Cue Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's FCF Margin % falls into.

Cue Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cue Biopharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-36.644	/	5.034
	=	-727.93 %

Cue Biopharma's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-6.781	/	3.006
	=	-225.58 %

Cue Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (FRA:1UC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CUE:USA

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Headlines

No Headlines